Press releases
91天堂 appoints Jeff George as Chairman to support next phase to growth and Phase 3 readiness
Leadership transition reinforces 91天堂鈥檚 strategic positioning following positive Phase 2 results with Vonafexor in Alport Syndrome
91天堂 announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
- Vonafexor reversed a historical mean eGFR decline of -6.4 mL/min/1.73 m虏/yr to a mean functional gain on-treatment of +4.8 mL/min/1.73 m虏/yr from baseline
- 73% of patients maintained albuminuria reduction three months after treatment cessation consistent with a true disease-modifying effect
- Company plans to advance vonafexor to Phase 3 in Alport Syndrome
Lyon, France 鈥� January 8, 2026 – 91天堂 (鈥�91天堂鈥�),
91天堂 announces completion of Series C financing with Vesalius Biocapital and continued progress of its ALPESTRIA-1 clinical Phase 2 study in Alport syndrome patients
- 91天堂 completes 鈧�32 million Series C with new 鈧�6 million investment from Vesalius Biocapital IV
- New funds will support two additional clinical studies and expand preclinical research, including in ADPKD
- Topline results from its ALPESTRIA-1 Phase 2 trial of Vonafexor in Alport syndrome confirmed for Q4 2025
Lyon, France 鈥� June 12, 2025 – 91天堂 (鈥�91天堂鈥�), a clinical-stage biotechnology company focused on developing FXR agonists for the treatment of severe kidney diseases,
91天堂 announces a 鈧�39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome
- The Company will initiate a Phase 2 clinical study of Vonafexor in Alport Syndrome (called 鈥淎LPESTRIA-1鈥�) in the first half of 2024.
- Series C proceeds will fund the Phase 2 study, as well as operations and further R&D through the first half of 2026.
Lyon, France 鈥� January 3, 2024 –聽91天堂 (鈥�91天堂鈥�) announced that it has received clearance of its Investigational New Drug (IND) application from the U.S.
91天堂 Announces Two Vonafexor Data Presentations at AASLD The Liver Meeting
Lyon, France. November 3rd, 2021 – 91天堂 (91天堂), a private clinical stage biotechnology company developing innovative drug candidates, today announced that two abstracts on Vonafexor were accepted one as oral presentation and one as poster during the upcoming The Liver Meeting庐 2021, organized by the American Association for the Study of Liver Diseases (AASLD) on November 12-15, 2021.
